Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.76
TKPYY's Cash-to-Debt is ranked lower than
67% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. TKPYY: 0.76 )
Ranked among companies with meaningful Cash-to-Debt only.
TKPYY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.7  Med: 0.99 Max: N/A
Current: 0.76
Equity-to-Asset 0.48
TKPYY's Equity-to-Asset is ranked lower than
70% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. TKPYY: 0.48 )
Ranked among companies with meaningful Equity-to-Asset only.
TKPYY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47  Med: 0.55 Max: 0.76
Current: 0.48
0.47
0.76
Interest Coverage 9.84
TKPYY's Interest Coverage is ranked lower than
72% of the 646 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. TKPYY: 9.84 )
Ranked among companies with meaningful Interest Coverage only.
TKPYY' s Interest Coverage Range Over the Past 10 Years
Min: 3.18  Med: 189.06 Max: 1856.28
Current: 9.84
3.18
1856.28
Piotroski F-Score: 5
Altman Z-Score: 2.46
Beneish M-Score: -2.34
WACC vs ROIC
4.88%
7.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 10.45
TKPYY's Operating Margin % is ranked higher than
56% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.38 vs. TKPYY: 10.45 )
Ranked among companies with meaningful Operating Margin % only.
TKPYY' s Operating Margin % Range Over the Past 10 Years
Min: -7.27  Med: 18.74 Max: 35.13
Current: 10.45
-7.27
35.13
Net Margin % 7.64
TKPYY's Net Margin % is ranked higher than
55% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. TKPYY: 7.64 )
Ranked among companies with meaningful Net Margin % only.
TKPYY' s Net Margin % Range Over the Past 10 Years
Min: -8.2  Med: 12.39 Max: 25.85
Current: 7.64
-8.2
25.85
ROE % 6.84
TKPYY's ROE % is ranked lower than
53% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.12 vs. TKPYY: 6.84 )
Ranked among companies with meaningful ROE % only.
TKPYY' s ROE % Range Over the Past 10 Years
Min: -6.33  Med: 8.85 Max: 15.12
Current: 6.84
-6.33
15.12
ROA % 3.34
TKPYY's ROA % is ranked lower than
53% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. TKPYY: 3.34 )
Ranked among companies with meaningful ROA % only.
TKPYY' s ROA % Range Over the Past 10 Years
Min: -3.29  Med: 6.12 Max: 12
Current: 3.34
-3.29
12
ROC (Joel Greenblatt) % 29.08
TKPYY's ROC (Joel Greenblatt) % is ranked higher than
70% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.08 vs. TKPYY: 29.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TKPYY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -19.36  Med: 48.9 Max: 207.72
Current: 29.08
-19.36
207.72
3-Year Revenue Growth Rate 5.20
TKPYY's 3-Year Revenue Growth Rate is ranked lower than
52% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. TKPYY: 5.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TKPYY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.2  Med: 5.05 Max: 11.6
Current: 5.2
0.2
11.6
3-Year EBITDA Growth Rate -4.40
TKPYY's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 536 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. TKPYY: -4.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TKPYY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -28.3  Med: -1.15 Max: 24.8
Current: -4.4
-28.3
24.8
3-Year EPS without NRI Growth Rate -18.50
TKPYY's 3-Year EPS without NRI Growth Rate is ranked lower than
79% of the 506 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. TKPYY: -18.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TKPYY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -24.5  Med: -0.8 Max: 31.4
Current: -18.5
-24.5
31.4
GuruFocus has detected 7 Warning Signs with Takeda Pharmaceutical Co Ltd $TKPYY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TKPYY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with TKPYY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:TEVA, NAS:MYL, OTCPK:SGIOY, OTCPK:ESALF, OTCPK:MKGAY, NYSE:PRGO, OTCPK:MTZPY, OTCPK:APNHF, OTCPK:HLUYY, OTCPK:IPSEY, NYSE:RDY, OTCPK:HKMPF, OTCPK:HYPMY, NYSE:VRX, NYSE:TARO, NYSE:PTHN, NAS:OPK, OTCPK:STDAF, NAS:NBIX, NAS:MDCO » details
Traded in other countries:TKD.Germany, 4502.Japan,
Takeda Pharmaceutical Co Ltd is engaged in the manufacturing, marketing and import and export of pharmaceutical drugs.

Takeda Pharmaceutical Co Ltd was founded on June 12, 1781 and was incorporated on January 29, 1925. The Company is primarily engaged in the any manufacture and sale of pharmaceuticals, food supplements, and chemical products such as polyurethane. The Company also produces food, agrochemicals, and environment-related products such as pollution detectors. It is also engaged in the research, development, and promotion of its products through its related companies in the US, Europe, and Asia.

Ratios

vs
industry
vs
history
PE Ratio 31.72
TKPYY's PE Ratio is ranked lower than
59% of the 453 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.06 vs. TKPYY: 31.72 )
Ranked among companies with meaningful PE Ratio only.
TKPYY' s PE Ratio Range Over the Past 10 Years
Min: 6.78  Med: 19.34 Max: 90.66
Current: 31.72
6.78
90.66
Forward PE Ratio 25.00
TKPYY's Forward PE Ratio is ranked lower than
76% of the 88 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.82 vs. TKPYY: 25.00 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 31.72
TKPYY's PE Ratio without NRI is ranked lower than
59% of the 447 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.19 vs. TKPYY: 31.72 )
Ranked among companies with meaningful PE Ratio without NRI only.
TKPYY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.78  Med: 19.34 Max: 90.66
Current: 31.72
6.78
90.66
Price-to-Owner-Earnings 23.21
TKPYY's Price-to-Owner-Earnings is ranked higher than
64% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.27 vs. TKPYY: 23.21 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TKPYY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.22  Med: 21.46 Max: 581.37
Current: 23.21
11.22
581.37
PB Ratio 2.13
TKPYY's PB Ratio is ranked higher than
62% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. TKPYY: 2.13 )
Ranked among companies with meaningful PB Ratio only.
TKPYY' s PB Ratio Range Over the Past 10 Years
Min: 1.22  Med: 1.55 Max: 2.44
Current: 2.13
1.22
2.44
PS Ratio 2.43
TKPYY's PS Ratio is ranked higher than
53% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. TKPYY: 2.43 )
Ranked among companies with meaningful PS Ratio only.
TKPYY' s PS Ratio Range Over the Past 10 Years
Min: 1.64  Med: 2.19 Max: 4.22
Current: 2.43
1.64
4.22
Price-to-Free-Cash-Flow 115.25
TKPYY's Price-to-Free-Cash-Flow is ranked lower than
89% of the 185 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.92 vs. TKPYY: 115.25 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TKPYY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.03  Med: 42.22 Max: 1453.4
Current: 115.25
10.03
1453.4
EV-to-EBIT 23.22
TKPYY's EV-to-EBIT is ranked lower than
59% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.61 vs. TKPYY: 23.22 )
Ranked among companies with meaningful EV-to-EBIT only.
TKPYY' s EV-to-EBIT Range Over the Past 10 Years
Min: -47.1  Med: 10.8 Max: 30.3
Current: 23.22
-47.1
30.3
EV-to-EBITDA 12.39
TKPYY's EV-to-EBITDA is ranked higher than
68% of the 478 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.32 vs. TKPYY: 12.39 )
Ranked among companies with meaningful EV-to-EBITDA only.
TKPYY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -438  Med: 10.6 Max: 237.7
Current: 12.39
-438
237.7
Shiller PE Ratio 12.58
TKPYY's Shiller PE Ratio is ranked higher than
94% of the 157 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.81 vs. TKPYY: 12.58 )
Ranked among companies with meaningful Shiller PE Ratio only.
TKPYY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.73  Med: 10.35 Max: 12.61
Current: 12.58
8.73
12.61
Current Ratio 1.73
TKPYY's Current Ratio is ranked lower than
64% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.25 vs. TKPYY: 1.73 )
Ranked among companies with meaningful Current Ratio only.
TKPYY' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 2.09 Max: 4
Current: 1.73
1.21
4
Quick Ratio 1.50
TKPYY's Quick Ratio is ranked lower than
58% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. TKPYY: 1.50 )
Ranked among companies with meaningful Quick Ratio only.
TKPYY' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 1.73 Max: 3.64
Current: 1.5
1
3.64
Days Inventory 160.56
TKPYY's Days Inventory is ranked lower than
71% of the 567 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.74 vs. TKPYY: 160.56 )
Ranked among companies with meaningful Days Inventory only.
TKPYY' s Days Inventory Range Over the Past 10 Years
Min: 132.84  Med: 162.63 Max: 180.99
Current: 160.56
132.84
180.99

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.49
TKPYY's Dividend Yield % is ranked higher than
87% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.62 vs. TKPYY: 3.49 )
Ranked among companies with meaningful Dividend Yield % only.
TKPYY' s Dividend Yield % Range Over the Past 10 Years
Min: 2.71  Med: 4.11 Max: 6.48
Current: 3.49
2.71
6.48
Dividend Payout Ratio 1.05
TKPYY's Dividend Payout Ratio is ranked lower than
89% of the 378 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.36 vs. TKPYY: 1.05 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TKPYY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.33  Med: 0.62 Max: 1.77
Current: 1.05
0.33
1.77
Forward Dividend Yield % 3.30
TKPYY's Forward Dividend Yield % is ranked higher than
84% of the 612 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. TKPYY: 3.30 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.49
TKPYY's 5-Year Yield-on-Cost % is ranked higher than
72% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. TKPYY: 3.49 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TKPYY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.71  Med: 4.11 Max: 6.48
Current: 3.49
2.71
6.48
3-Year Average Share Buyback Ratio 0.30
TKPYY's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. TKPYY: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TKPYY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.3  Med: 0 Max: 3.9
Current: 0.3
-0.3
3.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 8.06
TKPYY's Price-to-Tangible-Book is ranked lower than
79% of the 546 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. TKPYY: 8.06 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TKPYY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.85  Med: 7.02 Max: 13.07
Current: 8.06
1.85
13.07
Price-to-Intrinsic-Value-Projected-FCF 2.59
TKPYY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
51% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.61 vs. TKPYY: 2.59 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TKPYY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.14  Med: 1.44 Max: 2.6
Current: 2.59
1.14
2.6
Price-to-Median-PS-Value 1.11
TKPYY's Price-to-Median-PS-Value is ranked higher than
57% of the 538 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.22 vs. TKPYY: 1.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TKPYY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.81  Med: 1 Max: 1.57
Current: 1.11
0.81
1.57
Price-to-Graham-Number 3.37
TKPYY's Price-to-Graham-Number is ranked lower than
73% of the 331 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.17 vs. TKPYY: 3.37 )
Ranked among companies with meaningful Price-to-Graham-Number only.
TKPYY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.69  Med: 2.67 Max: 4.79
Current: 3.37
0.69
4.79
Earnings Yield (Greenblatt) % 4.30
TKPYY's Earnings Yield (Greenblatt) % is ranked higher than
56% of the 611 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. TKPYY: 4.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TKPYY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.3  Med: 7.5 Max: 34.9
Current: 4.3
3.3
34.9
Forward Rate of Return (Yacktman) % -27.85
TKPYY's Forward Rate of Return (Yacktman) % is ranked lower than
95% of the 353 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.48 vs. TKPYY: -27.85 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TKPYY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -46.9  Med: -18.25 Max: 15.8
Current: -27.85
-46.9
15.8

More Statistics

Revenue (TTM) (Mil) $15,891
EPS (TTM) $ 0.80
Beta0.34
Short Percentage of Float0.00%
52-Week Range $19.96 - 25.15
Shares Outstanding (Mil)1,567.34

Analyst Estimate

Mar17 Mar18
Revenue (Mil $) 15,350 16,243
EPS ($) 0.73 0.94
EPS without NRI ($) 0.73 0.94
EPS Growth Rate
(Future 3Y To 5Y Estimate)
1.82%
Dividends per Share ($) 0.80 0.80
» More Articles for TKPYY

Headlines

Articles On GuruFocus.com
Teva Is a Hold Nov 30 2016 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
5 Popular Asian Stocks Held By the Gurus Apr 16 2015 
Don't Quit on Teva Just Yet Feb 20 2014 
Soros´ Bet on Teva’s Transition (A Transition for Better or for Worse?) Dec 18 2013 
T. Rowe Price Japan Fund Top 5 New Buys Oct 17 2013 

More From Other Websites
Takeda Pharmaceutical Company Limited -- Moody's confirms Takeda Pharmaceutical's A1 ratings;... Feb 27 2017
Takeda and Cognition Kit partner in study to pilot wearable software in patients with Major... Feb 23 2017
Five-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn's and... Feb 17 2017
Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex... Feb 17 2017
Raleigh's PRA Health Sciences gains 60 employees after Takeda deal Feb 16 2017
Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc. Feb 16 2017
Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss Feb 10 2017
Takeda Presents $1 Million Gift to the Koch Institute for Integrative Cancer Research at MIT to... Feb 08 2017
Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q3, 2017 By the Numbers : February 2,... Feb 02 2017
Takeda Reports Q3 FY2016 Results and Improves Year-End Outlook Feb 01 2017
Exelixis Inks Partnership with Takeda for Cabometyx in Japan Jan 31 2017
Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel... Jan 30 2017
Ariad played hardball to boost Takeda buyout price, federal filings show Jan 20 2017
Takeda Recognized as One of the Global 100 Most Sustainable Corporations for Second Consecutive Year Jan 19 2017
Takeda Commences Cash Tender Offer for All Outstanding Shares of ARIAD Pharmaceuticals, Inc. Jan 19 2017
Takeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization... Jan 18 2017
Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short Jan 11 2017
Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement... Jan 11 2017
Former Ariad CEO Berger says Takeda deal was 'merely a matter of time' Jan 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)